RU2754089C2 - Композиции клеток, полученные из дедифференцированных перепрограммированных клеток - Google Patents

Композиции клеток, полученные из дедифференцированных перепрограммированных клеток Download PDF

Info

Publication number
RU2754089C2
RU2754089C2 RU2018144412A RU2018144412A RU2754089C2 RU 2754089 C2 RU2754089 C2 RU 2754089C2 RU 2018144412 A RU2018144412 A RU 2018144412A RU 2018144412 A RU2018144412 A RU 2018144412A RU 2754089 C2 RU2754089 C2 RU 2754089C2
Authority
RU
Russia
Prior art keywords
cells
cell
pancreatic
endoderm
heregulin
Prior art date
Application number
RU2018144412A
Other languages
English (en)
Russian (ru)
Other versions
RU2018144412A (ru
RU2018144412A3 (https=
Inventor
Алан Д. Агулник
Оливия КЕЛЛИ
Юки ОХИ
Аллан РОБИНС
Томас ШУЛЬЦ
Original Assignee
Виасайт, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/761,078 external-priority patent/US9109245B2/en
Application filed by Виасайт, Инк. filed Critical Виасайт, Инк.
Publication of RU2018144412A publication Critical patent/RU2018144412A/ru
Publication of RU2018144412A3 publication Critical patent/RU2018144412A3/ru
Application granted granted Critical
Publication of RU2754089C2 publication Critical patent/RU2754089C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2018144412A 2013-02-06 2014-02-06 Композиции клеток, полученные из дедифференцированных перепрограммированных клеток RU2754089C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/761,078 US9109245B2 (en) 2009-04-22 2013-02-06 Cell compositions derived from dedifferentiated reprogrammed cells
US13/761,078 2013-02-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015131279A Division RU2675928C2 (ru) 2013-02-06 2014-02-06 Композиции клеток, полученные из дедифференцированных перепрограммированных клеток

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021123311A Division RU2021123311A (ru) 2013-02-06 2021-08-04 Композиции клеток, полученных из дедифференцированных перепрограммированных клеток

Publications (3)

Publication Number Publication Date
RU2018144412A RU2018144412A (ru) 2019-03-25
RU2018144412A3 RU2018144412A3 (https=) 2020-02-14
RU2754089C2 true RU2754089C2 (ru) 2021-08-26

Family

ID=50239931

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018144412A RU2754089C2 (ru) 2013-02-06 2014-02-06 Композиции клеток, полученные из дедифференцированных перепрограммированных клеток
RU2015131279A RU2675928C2 (ru) 2013-02-06 2014-02-06 Композиции клеток, полученные из дедифференцированных перепрограммированных клеток

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015131279A RU2675928C2 (ru) 2013-02-06 2014-02-06 Композиции клеток, полученные из дедифференцированных перепрограммированных клеток

Country Status (8)

Country Link
EP (1) EP2954045A1 (https=)
JP (5) JP6517702B2 (https=)
AU (5) AU2014214879A1 (https=)
CA (2) CA3212301A1 (https=)
HK (1) HK1218139A1 (https=)
IL (5) IL311689B2 (https=)
RU (2) RU2754089C2 (https=)
WO (1) WO2014124172A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
EP3178924B1 (en) 2014-08-04 2019-12-25 Takeda Pharmaceutical Company Limited Method for proliferation of pancreatic progenitor cells
US10420803B2 (en) * 2016-04-14 2019-09-24 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
CN111349604B (zh) 2016-05-18 2023-12-12 学校法人庆应义塾 类器官培养用细胞培养基、培养方法及类器官
KR102448428B1 (ko) 2017-01-27 2022-09-30 가부시키가이샤 가네카 내배엽계 세포 집단, 및 다능성 세포로부터 3배엽 중 어느 하나의 세포 집단을 제조하는 방법
CN111565707A (zh) 2017-06-14 2020-08-21 森玛治疗公司 用于递送治疗物的装置和方法
CN111246864A (zh) * 2017-07-21 2020-06-05 森玛治疗公司 干细胞衍生的胰腺β细胞的重聚
EP3831931B1 (en) * 2018-08-03 2025-04-09 Orizuru Therapeutics, Inc. Cell production method
WO2020059892A1 (ja) * 2018-09-19 2020-03-26 武田薬品工業株式会社 インスリン産生細胞
CA3139292C (en) 2019-05-31 2025-06-10 Viacyte, Inc. CELL ENCAPSULATION DEVICES WITH REGULATED OXYGEN DIFFUSION DISTANCES
EP3976236A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates Inc. A biocompatible membrane composite
CN114173837A (zh) 2019-05-31 2022-03-11 W.L.戈尔及同仁股份有限公司 生物相容性膜复合材料
EP3975926A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates, Inc. A biocompatible membrane composite
WO2022026932A2 (en) 2020-07-31 2022-02-03 Vertex Pharmaceuticals Incorporated Differentiation of pancreatic endocrine cells
US20260097083A1 (en) * 2022-09-26 2026-04-09 Kyoto University Method for producing pancreatic endoderm cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059525A2 (en) * 1999-04-06 2000-10-12 Genentech, Inc. USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759039B2 (en) * 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
EP1366148A2 (en) * 2001-01-24 2003-12-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Differentiation of stem cells to pancreatic endocrine cells
CN101310012B (zh) * 2005-10-14 2012-05-09 明尼苏达大学董事会 非胚胎干细胞分化成具有胰腺表型的细胞
US20090298169A1 (en) * 2006-06-02 2009-12-03 The University Of Georgia Research Foundation Pancreatic and Liver Endoderm Cells and Tissue by Differentiation of Definitive Endoderm Cells Obtained from Human Embryonic Stems
JP2012508584A (ja) * 2008-11-14 2012-04-12 ヴィアサイト，インコーポレイテッド ヒト多能性幹細胞由来膵臓細胞のカプセル化
EP2421957B1 (en) * 2009-04-22 2020-11-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US9109245B2 (en) * 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
CN107603943B (zh) * 2009-04-27 2019-10-11 威盛细胞有限公司 支持多能细胞生长的小分子和其方法
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059525A2 (en) * 1999-04-06 2000-10-12 Genentech, Inc. USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUOTARI M.-A., et al. "ErbB Signaling Regulates Lineage Determination of Developing Pancreatic Islet Cells in Embryonic Organ Culture", Endocrinology. 2002; 143(11):4437-4446; DOI: 10.1210/en.2002-220382 abstract. *
ПОЛЯHОВСКИЙ О.Л. и др. "ERBB-онкогены-мишени моноклональных антител", Биохимия. 2012; 77(3): 289-311. *

Also Published As

Publication number Publication date
AU2014214879A1 (en) 2015-07-30
IL290717A (en) 2022-04-01
RU2018144412A (ru) 2019-03-25
IL290717B1 (en) 2024-06-01
JP2016506736A (ja) 2016-03-07
RU2675928C2 (ru) 2018-12-25
AU2022200075B2 (en) 2023-02-02
CA2898431C (en) 2023-10-17
AU2022200075A1 (en) 2022-02-03
IL311689A (en) 2024-05-01
HK1218139A1 (zh) 2017-02-03
JP2020178694A (ja) 2020-11-05
AU2023202507B2 (en) 2025-12-04
IL283088B (en) 2022-04-01
IL290717B2 (en) 2024-10-01
IL283088A (en) 2021-06-30
AU2022200075C1 (en) 2023-07-06
CA2898431A1 (en) 2014-08-14
AU2019201314B2 (en) 2021-10-14
WO2014124172A1 (en) 2014-08-14
AU2026201562A1 (en) 2026-03-19
AU2019201314A1 (en) 2019-03-14
JP7550830B2 (ja) 2024-09-13
JP2019146578A (ja) 2019-09-05
IL311689B1 (en) 2025-08-01
CA3212301A1 (en) 2014-08-14
IL311689B2 (en) 2025-12-01
IL239953B (en) 2021-05-31
JP2023017838A (ja) 2023-02-07
JP6517702B2 (ja) 2019-05-22
JP2025000625A (ja) 2025-01-07
EP2954045A1 (en) 2015-12-16
IL321825A (en) 2025-08-01
JP6721752B2 (ja) 2020-07-15
AU2023202507A1 (en) 2023-05-11
RU2015131279A (ru) 2017-03-13
JP7250731B2 (ja) 2023-04-03
RU2018144412A3 (https=) 2020-02-14
IL239953A0 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
JP7490035B2 (ja) 多能性幹細胞の膵臓内胚葉細胞（ＰＥＣ）および内分泌細胞へのｉｎ ｖｉｔｒｏ分化
JP7550830B2 (ja) 脱分化したリプログラミングされた細胞から導出された細胞組成物
US20240409900A1 (en) Cell encapsulation device comprising a pancreatic progenitor cell population